2021 American Transplant Congress
Pilot Evaluation of Prognosis After Liver Transplantation in Patients with a History of Hepatocellular Carcinoma and Pd-1 Inhibition
*Purpose: The successful applications of programmed death protein-1 (PD-1) inhibitors in cancer therapy has led to an expanding use of immunotherapy in oncolog Liver transplantation…2020 American Transplant Congress
Living Donor Liver Transplantation Should Be Considered Cautiously in Recurrent Hepatocellular Carcinoma within the Milan Criteria after Curative Liver Resection
*Purpose: Insufficient data are available about patient survival following different treatments for recurrent hepatocellular carcinoma (HCC) after primary hepatectomy. We retrospectively evaluated the effects of…2020 American Transplant Congress
Factors Associated with Hepatocellular Carcinoma Understaging for Liver Transplantation, and Variation in Understaging by Transplant Center
1Hospital of the University of Pennsylvania, Philadelphia, PA, 2University of Miami, Miami, FL
*Purpose: Hepatocellular carcinoma (HCC) may be cured by liver transplantation (LT) in selected patients, though recurrence rates remain high. Patients who are reported as within…2020 American Transplant Congress
Younger Age is Associated with Improved Survival in Patients Undergoing Liver Transplantation Alone for Metastatic Neuroendocrine Tumors
University of Kentucky, Lexington, KY
*Purpose: Neuroendocrine tumor (NET) metastases are a major cause of morbidity and mortality. The role of liver transplantation to treat unresectable metastases from NET is…2020 American Transplant Congress
Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
1Hiroshima University, Hiroshima, Japan, 2University of Miami, Miami, FL
*Purpose: Development of an effective adjuvant therapy to prevent HCC recurrence after liver transplantation (LT) is an important medical requirement. Immunosuppressive regimens currently used after…2020 American Transplant Congress
Prognostic Index of Circulating Tumor Cells for Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation
*Purpose: Liver transplantation (LT) is an effective option for hepatocellular carcinoma (HCC) and end-stage liver cirrhosis. However, organ shortage and tumor recurrence are the main…2020 American Transplant Congress
Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond UCSF Criteria: Tumor Biology Not the Tumor Number Decide the Long Term Outcome- A Single Center Retrospective Analysis of Using Extended Criteria
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan
*Purpose: HCC is the fifth most common cancer and the third most frequent cause of cancer deaths worldwide. After its introduction for LT in HCC…2020 American Transplant Congress
Contralateral Upper Tracturothelial Carcinoma after Primary Radical Nephroureterectomy in Kidney Transplant Patients
Capital Medical University, Beijing, China
*Purpose: The purpose of the present study was to evaluate the incidence and risk factors of contralateral upper tract urothelial carcinoma (UTUC) after primary radical…2020 American Transplant Congress
The Impact of Initial Alpha-Fetoprotein >100 but <1,000 ng/mL and Pre-Transplant alpha-Fetoprotein Reduction on Outcomes after Liver Transplant in Patients with Hepatocellular Carcinoma
1Department of Medicine, UCSF, San Francisco, CA, 2Department of Medicine, USC, Los Angeles, CA
*Purpose: Under current UNOS policy, hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) >1,000 ng/mL are required to show a reduction in AFP to 100 but2020 American Transplant Congress
Kidney Transplantation after Multiple Myeloma: The Last 2 Decades
Medicine, Northwell Health, Manhasset, NY
*Purpose: Due to recent advances, patients with a history of multiple myeloma (MM) and ESKD are more frequently offered kidney transplantation (Ktx). Existing literature does…
American Transplant Congress abstracts